Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $48.13 Average Price Target from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $48.1250.

AVTX has been the subject of a number of recent analyst reports. Mizuho raised their target price on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. HC Wainwright reduced their target price on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price for the company. Citizens Jmp reduced their target price on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Finally, Wolfe Research assumed coverage on Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 target price for the company.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $16.13 on Friday. Avalo Therapeutics has a one year low of $3.58 and a one year high of $24.27. The business has a fifty day moving average of $15.75 and a two-hundred day moving average of $16.40. The company has a market cap of $847.95 million, a P/E ratio of -2.95 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. Sell-side analysts predict that Avalo Therapeutics will post -2.72 EPS for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total value of $1,514,020.71. Following the sale, the insider owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. This represents a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,457 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the chief financial officer directly owned 423 shares in the company, valued at $5,596.29. This trade represents a 95.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 138,078 shares of company stock valued at $2,501,346. Insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

Several large investors have recently bought and sold shares of AVTX. Caligan Partners LP acquired a new stake in Avalo Therapeutics in the third quarter valued at $10,592,000. Balyasny Asset Management L.P. acquired a new stake in Avalo Therapeutics in the third quarter valued at $10,390,000. Vanguard Group Inc. grew its holdings in Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after purchasing an additional 525,696 shares during the last quarter. Millennium Management LLC grew its holdings in Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after purchasing an additional 522,548 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in Avalo Therapeutics in the fourth quarter valued at $8,637,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.